GO:0005112 Notch binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005112 Notch binding is a molecular function defined as binding to a Notch (N) protein, a surface receptor.
• Notch binding is mediated by canonical DSL ligands (Delta, Serrate, Lag-2) and is structurally conserved from invertebrates to humans.
• The Notch intracellular domain (NICD) also binds nuclear effector CSL to regulate transcription, a distinct but related binding event.
• Notch binding is central to cell-fate decisions, tissue homeostasis, and is dysregulated in cancers, lung diseases, and graft-versus-host disease.
• Experimental assays for Notch binding include flow cytometry, Dynabeads-based ligand binding, and structural approaches.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of Notch binding in disease.
Description
Notch binding (GO:0005112) is a molecular function that describes the physical interaction between a protein and a Notch receptor, a surface protein that mediates cell-cell communication. This binding event is the first step in Notch signaling, a conserved pathway that controls cell fate, proliferation, and differentiation across metazoans. The QuickGO definition specifies binding to a Notch (N) protein, a surface receptor, and the term encompasses interactions with both canonical ligands and intracellular effectors. Researchers study Notch binding to understand developmental biology, tissue regeneration, and diseases ranging from cancer to inflammatory conditions. The interaction is structurally conserved, with key binding motifs identified in transcriptional regulators that engage the Notch nuclear effector CSL. Experimental protocols for measuring Notch binding, such as flow cytometry and Dynabeads-based assays, have been established to quantify ligand-receptor interactions. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0005112, its mechanisms, key genes, and methods for investigation.
Notch binding At A Glance
| GO ID | GO:0005112 |
|---|---|
| GO term | Notch binding |
| Ontology | molecular_function |
| Synonym | N binding, N ligand, Notch ligand, Notch receptor binding |
| Major function | Binding to Notch surface receptor, initiating or modulating Notch signaling |
| Definition | Binding to a Notch (N) protein, a surface receptor |
| Related effectors | CSL (nuclear effector), Delta/Serrate/Lag-2 ligands |
| Structural basis | Conserved binding motifs; C2 phospholipid-binding domain in Delta contributes to robust signaling |
| Experimental assays | Flow cytometry, Dynabeads-based binding assays |
What Is GO:0005112?
GO:0005112 Notch binding is defined by QuickGO as the binding to a Notch (N) protein, a surface receptor. In practice, this molecular function encompasses the direct physical interaction between a protein and the Notch receptor, including canonical ligand-receptor binding at the cell surface and interactions with the Notch intracellular domain (NICD) in the nucleus. Synonyms include N binding, N ligand, Notch ligand, and Notch receptor binding. The term is a molecular_function in the Gene Ontology and is distinct from downstream signaling events, focusing specifically on the binding event itself.
Why Is Notch binding Important in Cell Biology?
Notch binding is a fundamental molecular event that governs cell-fate decisions, tissue patterning, and stem cell maintenance. Dysregulation of Notch binding is implicated in a wide range of human diseases, including cancers, lung diseases, and intestinal graft-versus-host disease. Understanding the structural and biochemical basis of Notch binding provides opportunities for therapeutic intervention and for developing targeted research models.
• Notch binding initiates a conserved signaling pathway essential for development and tissue homeostasis.
• Mutations affecting Notch binding are linked to cancers and developmental disorders.
• Notch binding is a therapeutic target in inflammatory diseases such as graft-versus-host disease.
• Structural insights into Notch-ligand interactions inform drug design.
• Assays for Notch binding enable screening of modulators.
• The C2 phospholipid-binding domain in Delta enhances Notch signaling robustness.
• Notch binding to CSL is critical for transcriptional regulation.
• Conformational heterogeneity of NICD binding to effectors tunes biological responses.
• Notch binding is studied in lung diseases, including COPD and cancer.
• CRISPR models allow causal testing of Notch binding genes in vivo.
Molecular Mechanism of Notch binding
Ligand-Receptor Recognition at the Cell Surface
In simple terms: Notch binding starts when a ligand on one cell grabs the Notch receptor on a neighboring cell.
Canonical Notch ligands (Delta, Serrate, Lag-2) bind to the Notch receptor ectodomain through conserved DSL domains. This interaction is structurally conserved and involves multiple epidermal growth factor (EGF)-like repeats in Notch. The binding triggers a conformational change that exposes a cleavage site, leading to receptor activation. The C2 phospholipid-binding domain in Delta contributes to robust Notch signalling by stabilizing the ligand-receptor complex.
Intracellular Domain Binding to Nuclear Effectors
In simple terms: After cleavage, the Notch intracellular domain travels to the nucleus and binds to CSL to control gene expression.
The Notch intracellular domain (NICD) is released upon ligand binding and translocates to the nucleus, where it binds the CSL transcription factor. Structurally conserved binding motifs in transcriptional regulators mediate this interaction. Conformational heterogeneity of NICD binding to effector proteins tunes the biological response, as described by Bertagna et al..
Structural Determinants of Notch Binding
In simple terms: The shape and chemical properties of Notch and its partners determine how tightly they bind.
Structural studies have revealed that Notch receptor-ligand interactions rely on calcium-binding EGF-like repeats and specific amino acid residues. The binding interface is highly conserved across species. The C2 domain in Delta provides additional membrane-binding surfaces that enhance signaling. These structural insights are critical for designing inhibitors or modulators of Notch binding.
Regulation of Notch Binding by Post-Translational Modifications
In simple terms: Chemical tags on Notch or its ligands can strengthen or weaken their binding.
Glycosylation of Notch EGF repeats by Fringe enzymes modulates ligand binding specificity. Phosphorylation and ubiquitination of NICD affect its stability and binding to CSL. The C2 domain in Delta may also be regulated by lipid interactions. These modifications fine-tune Notch binding in a context-dependent manner.
Conformational Dynamics and Binding Affinity
In simple terms: Notch binding is not rigid; flexible regions allow it to adapt to different partners.
The Notch intracellular domain exhibits biologically tuned disorder, allowing it to bind multiple effectors with varying affinities. This conformational heterogeneity is essential for differential signaling outcomes. Binding motifs in transcriptional regulators to CSL are structurally conserved but exhibit dynamic behavior. Such flexibility enables Notch to integrate diverse cellular signals.
Key Genes Involved in GO:0005112 Notch binding
The following genes and proteins are central to Notch binding (GO:0005112), based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NOTCH1 | Notch receptor; binds DSL ligands and CSL | Mutations in NOTCH1 are linked to cancers and developmental disorders |
| NOTCH2 | Notch receptor; mediates cell-cell signaling | Implicated in intestinal graft-versus-host disease |
| NOTCH3 | Notch receptor; vascular smooth muscle function | Associated with CADASIL and other vascular diseases |
| NOTCH4 | Notch receptor; mammary gland development | Role in breast cancer and stem cell regulation |
| DLL1 | Delta-like ligand; binds Notch receptors | Key in developmental patterning and tissue homeostasis |
| DLL3 | Delta-like ligand; inhibits Notch signaling | Target in small cell lung cancer |
| DLL4 | Delta-like ligand; regulates angiogenesis | Critical for vascular development and tumor angiogenesis |
| JAG1 | Jagged1 ligand; binds Notch receptors | Mutations cause Alagille syndrome |
| JAG2 | Jagged2 ligand; binds Notch receptors | Role in skeletal muscle and cancer |
| CSL (RBPJ) | Nuclear effector; binds NICD | Central to Notch transcriptional regulation |
| MAML1 | Mastermind-like coactivator; binds NICD-CSL complex | Enhances Notch target gene expression |
| FBXW7 | Ubiquitin ligase; regulates NICD stability | Mutations linked to cancer and Notch turnover |
| ADAM10 | Protease; cleaves Notch upon ligand binding | Required for Notch activation |
| PSEN1 | Gamma-secretase subunit; cleaves Notch | Mutations in Alzheimer's disease and cancer |
| LFNG | Fringe glycosyltransferase; modifies Notch | Modulates ligand binding specificity |
| MFNG | Fringe glycosyltransferase; modifies Notch | Affects Notch signaling in development |
| RFNG | Fringe glycosyltransferase; modifies Notch | Regulates Notch binding in neurogenesis |
How Is Notch binding Regulated?
Notch binding is regulated at multiple levels. Glycosylation of Notch EGF repeats by Fringe enzymes (LFNG, MFNG, RFNG) modulates ligand binding specificity. Phosphorylation and ubiquitination of the Notch intracellular domain affect its stability and binding to CSL. The C2 phospholipid-binding domain in Delta contributes to robust Notch signalling by stabilizing the ligand-receptor interaction. Conformational heterogeneity of NICD binding to effector proteins provides an additional layer of regulation, tuning biological responses. These regulatory mechanisms ensure context-dependent Notch activation.
Notch binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NOTCH1 | T-cell acute lymphoblastic leukemia | Knockout or point mutation in T-ALL cell lines |
| DLL3 | Small cell lung cancer | Overexpression or knockout in lung cancer models |
| JAG1 | Alagille syndrome | Knock-in of patient mutations in iPSCs |
| NOTCH2 | Intestinal graft-versus-host disease | Knockout in mouse models of GVHD |
| DLL4 | Tumor angiogenesis | Knockout in endothelial cells |
Notch binding in Cancer
Dysregulated Notch binding is implicated in multiple cancers. NOTCH1 mutations are common in T-cell acute lymphoblastic leukemia and other malignancies. DLL3, a ligand that inhibits Notch signaling, is a therapeutic target in small cell lung cancer. DLL4 regulates tumor angiogenesis and is being explored as an anti-angiogenic target. Understanding Notch binding in cancer informs the development of targeted therapies.
Notch binding in Lung Diseases
NOTCH signaling, initiated by Notch binding, plays a role in lung development and disease. Aberrant Notch binding is associated with chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and lung cancer. Targeting Notch binding may offer therapeutic strategies for these conditions.
Notch binding in Graft-versus-Host Disease
Notch signaling drives intestinal graft-versus-host disease (GVHD) in mice and nonhuman primates. Blocking Notch binding with inhibitors reduces GVHD severity, suggesting that Notch binding is a therapeutic target in transplantation.
Notch binding in Developmental Disorders
Mutations in JAG1 cause Alagille syndrome, a developmental disorder affecting the liver, heart, and other organs. These mutations impair Notch binding, highlighting the importance of this molecular function in human development.
From Notch binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NOTCH1 binding affect T-cell development? | NOTCH1 knockout in Jurkat or primary T cells |
| Can a point mutation in JAG1 disrupt Notch binding? | JAG1 point-mutation knock-in in HEK293T cells |
| Does DLL4 overexpression enhance angiogenesis? | DLL4 overexpression in endothelial cells |
| How does NICD binding to CSL regulate transcription? | CSL knockout with NICD knock-in |
| Does Notch binding inhibition reduce GVHD? | NOTCH2 knockout in mouse GVHD models |
| What is the role of Fringe glycosylation in Notch binding? | LFNG knockout in cell lines |
How to Study the Notch binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Ligand-receptor binding on cell surface | Quantifying Notch binding affinity |
| Dynabeads binding assay | Protein-protein interactions | Isolating Notch binding complexes |
| X-ray crystallography | Atomic structure of binding interface | Designing Notch binding inhibitors |
| CRISPR screen | Genes regulating Notch binding | Discovering novel pathway components |
| Co-immunoprecipitation | Physical interaction between Notch and partners | Validating binding in cells |
| Surface plasmon resonance | Binding kinetics (kon, koff) | Measuring affinity of Notch-ligand interactions |
| FRET/BRET | Real-time binding dynamics in live cells | Studying conformational changes |
Flow Cytometry-Based Notch Ligand Binding Assay
Flow cytometry can quantify Notch ligand binding to receptors on the cell surface. This method uses fluorescently labeled ligands or receptors to measure binding affinity and specificity. It is suitable for screening modulators of Notch binding.
Dynabeads-Based Notch-Ligand Binding Assays
Dynabeads coated with Notch ligands or receptors enable pull-down and binding assays. This protocol allows for the isolation of binding complexes and downstream analysis. It is useful for biochemical characterization of Notch binding.
Structural Approaches to Study Notch Binding
X-ray crystallography and cryo-EM have revealed the structural basis of Notch receptor-ligand interactions. These methods identify key binding residues and conformational changes. Structural insights guide the design of Notch binding modulators.
CRISPR Screens for Notch Binding Regulators
Genome-wide CRISPR screens can identify genes that regulate Notch binding and signaling. Such screens have been used to discover modulators of Notch-driven GVHD. They enable unbiased discovery of novel components in the Notch binding pathway.
How CRISPR Can Be Used to Study GO:0005112 Notch binding
Knockout
CRISPR knockout of Notch receptors or ligands (e.g., NOTCH1, DLL4) abolishes Notch binding, enabling loss-of-function studies. Knockout models are used to assess the requirement for Notch binding in development and disease.
Point Mutation
Point mutations in Notch binding interfaces (e.g., in JAG1 or NOTCH1) can disrupt binding without affecting protein expression. These models help dissect the specific contribution of individual residues to Notch binding.
Knock-in
Knock-in of tagged Notch receptors (e.g., GFP-NOTCH1) allows visualization and pull-down of binding complexes. Knock-in of patient mutations (e.g., JAG1) models disease-associated binding defects.
Overexpression
Overexpression of Notch ligands or receptors (e.g., DLL4, NOTCH1) enhances Notch binding and signaling. This approach is used to study gain-of-function effects in cancer and angiogenesis.
How EDITGENE Supports Notch binding Research
Researchers studying Notch binding-related genes often need to determine whether a candidate gene is causally involved in the binding event or downstream signaling. EDITGENE provides CRISPR-based services to generate precise cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for Notch binding research.
Frequently Asked Questions About Notch binding
What is GO:0005112 Notch binding?
GO:0005112 Notch binding is a molecular function defined as binding to a Notch (N) protein, a surface receptor.
What genes are involved in Notch binding?
Key genes include NOTCH1-4, DLL1/3/4, JAG1/2, CSL (RBPJ), and MAML1.
How is Notch binding measured?
Flow cytometry and Dynabeads-based binding assays are commonly used.
What diseases are associated with Notch binding?
Cancers, lung diseases, graft-versus-host disease, and Alagille syndrome.
What is the role of CSL in Notch binding?
CSL is a nuclear effector that binds the Notch intracellular domain to regulate transcription.
How does Delta contribute to Notch binding?
The C2 phospholipid-binding domain in Delta stabilizes the ligand-receptor complex for robust signaling.
Can CRISPR be used to study Notch binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal studies.
What is the structural basis of Notch binding?
Conserved EGF-like repeats and calcium-binding sites mediate receptor-ligand interactions.
How is Notch binding regulated?
Glycosylation by Fringe enzymes and phosphorylation of NICD modulate binding.
What assays are used for Notch binding screening?
Flow cytometry, Dynabeads assays, and CRISPR screens are used.
Conclusion
GO:0005112 Notch binding is a central molecular function that initiates Notch signaling, a pathway critical for development and tissue homeostasis. Its dysregulation is implicated in cancers, lung diseases, and graft-versus-host disease. Structural and biochemical studies have elucidated the binding interfaces and regulatory mechanisms. CRISPR-based models provide powerful tools to dissect the causal roles of Notch binding genes in health and disease. Continued research on Notch binding will inform therapeutic strategies targeting this pathway.
References
- 1. Hall DP et al.. 2019. Structurally conserved binding motifs of transcriptional regulators to notch nuclear effector CSL.. Exp Biol Med (Maywood) 244(17):1520-1529 PMID: 31544502
- 2. Tkachev V et al.. 2023. Notch signaling drives intestinal graft-versus-host disease in mice and nonhuman primates.. Sci Transl Med 15(702):eadd1175 PMID: 37379368
- 3. Varshney S et al.. 2017. Notch Ligand Binding Assay Using Flow Cytometry.. Bio Protoc 7(23) PMID: 29333477
- 4. Martins T et al.. 2021. The conserved C2 phospholipid-binding domain in Delta contributes to robust Notch signalling.. EMBO Rep 22(10):e52729 PMID: 34347930
- 5. Bertagna A et al.. 2008. The effects of conformational heterogeneity on the binding of the Notch intracellular domain to effector proteins: a case of biologically tuned disorder.. Biochem Soc Trans 36(Pt 2):157-66 PMID: 18363556
- 6. Jiang J et al.. 2017. NOTCH signaling in lung diseases.. Exp Lung Res 43(4-5):217-228 PMID: 28636457
- 7. Sawaguchi S et al.. 2017. Protocol for Notch-ligand Binding Assays Using Dynabeads.. Bio Protoc 7(20):e2582 PMID: 34595264
- 8. Handford PA et al.. 2018. Structural Insights into Notch Receptor-Ligand Interactions.. Adv Exp Med Biol 1066:33-46 PMID: 30030820
